文献速递心血管介入CT

基于冠状动脉CTA的人工智能斑块定量在接受经导管主动脉瓣植入术患者中的预后价值

Prognostic value of coronary CTA-based AI plaque quantification in patients undergoing transcatheter aortic valve implantation.
PubMed 文献 · Eur J Radiol · 2025-10-04

本研究为观察性队列研究,纳入128例TAVI术前CTA患者,采用AI-QCPA定量分析冠状动脉斑块。1年内24例发生MACE,发生MACE者总斑块体积、钙化斑块体积、非钙化斑块体积及低衰减斑块体积中位数均显著更高;多变量回归显示非钙化斑块体积最高四分位(OR 4.56)和低衰减斑块体积最高四分位(OR 3.70)与MACE独立相关。

要点

  • TAVI术前CTA可同步评估冠状动脉斑块,AI-QCPA定量斑块体积与1年MACE独立相关。
  • 非钙化斑块体积最高四分位者MACE风险OR 4.56(95%CI 1.61-12.89),低衰减斑块体积最高四分位者OR 3.70(95%CI 1.29-10.60)。
  • 发生MACE者总斑块体积、钙化斑块体积、非钙化斑块体积及低衰减斑块体积中位数均显著高于未发生者。

核心结论

  • 接受TAVI的患者冠状动脉斑块体积高,AI-QCPA定量的斑块体积与TAVI术后1年MACE发生独立相关。

研究设计与样本

  • 观察性队列研究,纳入128例因TAVI规划行CTA并同步评估冠状动脉粥样硬化的患者;使用192层双源SIEMENS Force CT扫描仪,未使用硝酸甘油或β受体阻滞剂等预用药;参考标准为TAVI术后1年内MACE(全因死亡、卒中、心肌梗死、心力衰竭住院或非计划血运重建的复合终点)。

诊断标准与关键数值

  • AI-QCPA定量斑块体积,发生MACE者总斑块体积、钙化斑块体积、非钙化斑块体积及低衰减斑块体积中位数均显著高于未发生MACE者;校正STS评分、他汀使用及TAVI前血运重建后,非钙化斑块体积最高四分位与MACE独立相关(OR 4.56,95%CI 1.61-12.89;p=0.004),低衰减斑块体积最高四分位与MACE独立相关(OR 3.70,95%CI 1.29-10.60;p=0.015);校正冠状动脉狭窄后,总斑块及所有斑块亚型均与MACE独立相关。

临床应用与阅片要点

  • TAVI术前CTA可同步进行AI-QCPA冠状动脉斑块定量分析,关注非钙化斑块体积和低衰减斑块体积最高四分位患者的MACE风险。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND: Coronary artery disease can be concomitantly evaluated as part of the pre-transcatheter aortic valve implantation (TAVI) CT angiography (CTA). More recently it has been possible to perform quantitative plaque analysis on coronary CT angiography (CCTA). In this study, we aimed to assess the prognostic value of quantitative plaque volumes using Artificial Intelligence Quantified Coronary Plaque Analysis (AI-QCPA) on pre-TAVI CTA.

METHODS: This observational cohort study included patients who underwent CTA for TAVI planning with concomitant evaluation for coronary atherosclerosis. Studies were performed on a 192-slice dual-source SIEMENS Force CT scanner without administration of pre-medication such as nitroglycerin or beta-blockers. We examined coronary plaque characteristics in TAVI patients with AI-QCPA and assessed differences in plaque volumes between patients who developed major adverse cardiac events (MACE) at one year versus those who did not. MACE was defined as a composite of all-cause mortality, stroke, myocardial infarction, heart failure hospitalization, or unplanned revascularization within 1-year post-TAVI.

RESULTS: AI-QCPA was performed in 128 patients, with mean age of 80.1 ± 9.6 years (51.6 % male). A total of 24 patients developed MACE at 1 year. Median total plaque volume (TPV), calcified plaque volume (CPV), non-calcified plaque volume (NCPV), and low-attenuation plaque volume (LAPV) were significantly higher in patients who developed MACE. Multivariable regression analysis adjusting for Society of Thoracic Surgeons (STS) score, statin use, and revascularization pre-TAVI, showed that the highest quartile of NCPV (OR 4.56, 95 % CI 1.61-12.89; p = 0.004) and LAPV (OR 3.70, 95 % CI 1.29-10.60; p = 0.015) were independently associated with MACE. When adjusted for coronary stenosis total plaque and all plaque subtypes were independently associated with MACE.

CONCLUSION: There is high volume of coronary plaque in patients undergoing TAVI assessed by AI-QCPA which is independently associated with the development of MACE one year post-TAVI.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Hussain K, Lee K, Balasubramanian SS, et al. Prognostic value of coronary CTA-based AI plaque quantification in patients undergoing transcatheter aortic valve implantation. Eur J Radiol. 2025. PMID: 41075372. doi:10.1016/j.ejrad.2025.112445

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。